ALTHE Theraclion SA
Theraclion SA provides therapeutic ultrasound technology for seamless vein care. It offers SONOVEIN, a robotic solution for the non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for the echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment to protect the patient's skin and optimize image quality. The company was incorporated in 2004 and is headquartered in Malakoff, France.…
Industry Peers
Medical DevicesKey Statistics
About Theraclion (EPA: ALTHE)
›
Theraclion (EPA: ALTHE) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 40 employees.
The shares were at 0.5740 EUR on 19 November 2026, down 11.1% over 52 weeks. Its 52-week range is 0.4020 EUR to 0.9300 EUR: the price is 38.3% below the high and 42.8% above the low.
Its market capitalisation is 42.35M EUR.
Theraclion reports return on equity of 219.8% and revenue down 20.9% year over year.
Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock, with an average rating of Strong Buy; their mean price target of 2.032 EUR is 254.0% above the current price.